The B-cell receptor signaling pathway is active in diffuse large B-cell lymphomas, with increased expression of MYC and BCL2 protein. The overall response rate was 60% for relapsed/refractory non–germinal center double-expressor lymphoma patients treated with ibrutinib.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6341198 | PMC |
| http://dx.doi.org/10.1182/bloodadvances.2018026401 | DOI Listing |
Publication Analysis
Top Keywords
treated ibrutinib
8
outcomes patients
4
patients relapsed/refractory
4
relapsed/refractory double-expressor
4
double-expressor b-cell
4
b-cell lymphoma
4
lymphoma treated
4
ibrutinib monotherapy
4
monotherapy b-cell
4
b-cell receptor
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!